Guardant Health Inc (NASDAQ:GH) CEO Helmy Eltoukhy sold 78,660 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $72.34, for a total value of $5,690,264.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Helmy Eltoukhy also recently made the following trade(s):
- On Wednesday, May 1st, Helmy Eltoukhy sold 131,340 shares of Guardant Health stock. The stock was sold at an average price of $65.32, for a total value of $8,579,128.80.
- On Monday, April 22nd, Helmy Eltoukhy sold 90,000 shares of Guardant Health stock. The stock was sold at an average price of $65.28, for a total value of $5,875,200.00.
Shares of GH traded down $0.27 during midday trading on Friday, reaching $76.33. 20,928 shares of the stock were exchanged, compared to its average volume of 1,075,995. Guardant Health Inc has a 12-month low of $27.04 and a 12-month high of $106.58. The company has a market capitalization of $6.68 billion and a PE ratio of -27.19.
Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The company had revenue of $36.66 million during the quarter, compared to the consensus estimate of $32.12 million. Equities analysts forecast that Guardant Health Inc will post -1.46 earnings per share for the current year.
Several hedge funds have recently modified their holdings of GH. Temasek Holdings Private Ltd bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $60,633,000. Orbimed Advisors LLC bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $57,681,000. BlackRock Inc. bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $41,894,000. Jennison Associates LLC bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $31,700,000. Finally, Lord Abbett & CO. LLC bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $20,024,000. 68.54% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on GH. Zacks Investment Research downgraded Guardant Health from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Wednesday, March 13th. Canaccord Genuity began coverage on Guardant Health in a research note on Tuesday, April 16th. They set a “buy” rating and a $90.00 price target for the company. JPMorgan Chase & Co. raised their price target on Guardant Health from $42.00 to $85.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Finally, Cowen raised their price target on Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $83.50.
COPYRIGHT VIOLATION NOTICE: “Guardant Health Inc (GH) CEO Helmy Eltoukhy Sells 78,660 Shares” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2019/05/17/guardant-health-inc-gh-ceo-helmy-eltoukhy-sells-78660-shares.html.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: What is a Buy-Side Analyst?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.